Literature DB >> 25717204

Gemcitabine and Carboplatin (renally dosed) regimen for bladder cancer.

E Ryan Pritchard1, J Aubrey Waddell1, Dominic A Solimando1.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2015        PMID： 25717204      PMCID： PMC4336011          DOI： 10.1310/hpj5002-103

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  20 in total

Review 1.  Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.

Authors:  F Roila; J Herrstedt; M Aapro; R J Gralla; L H Einhorn; E Ballatori; E Bria; R A Clark-Snow; B T Espersen; P Feyer; S M Grunberg; P J Hesketh; K Jordan; M G Kris; E Maranzano; A Molassiotis; G Morrow; I Olver; B L Rapoport; C Rittenberg; M Saito; M Tonato; D Warr
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

2.  Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia.

Authors:  Jon D Herrington; Hai T Tran; Mark W Riggs
Journal:  Cancer Chemother Pharmacol       Date:  2005-08-25       Impact factor: 3.333

3.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

4.  Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.

Authors:  Luigi Dogliotti; Giacomo Cartenì; Salvatore Siena; Oscar Bertetto; Andrea Martoni; Aldo Bono; Dino Amadori; Haluk Onat; Luca Marini
Journal:  Eur Urol       Date:  2006-12-26       Impact factor: 20.096

5.  Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.

Authors:  Kazuhiro Iwasaki; Wataru Obara; Yoichiro Kato; Ryo Takata; Susumu Tanji; Tomoaki Fujioka
Journal:  Jpn J Clin Oncol       Date:  2012-12-28       Impact factor: 3.019

6.  Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features.

Authors:  C Shannon; C Crombie; A Brooks; H Lau; M Drummond; H Gurney
Journal:  Ann Oncol       Date:  2001-07       Impact factor: 32.976

7.  Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study.

Authors:  Takuya Koie; Chikara Ohyama; Yasuhiro Hashimoto; Shingo Hatakeyama; Hayato Yamamoto; Takahiro Yoneyama; Noritaka Kamimura
Journal:  Int J Clin Oncol       Date:  2012-07-19       Impact factor: 3.402

8.  Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?

Authors:  Corine Ekhart; Sjoerd Rodenhuis; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  Cancer Chemother Pharmacol       Date:  2008-11-07       Impact factor: 3.333

9.  Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.

Authors:  Helena Linardou; Gerassimos Aravantinos; Eleni Efstathiou; Charalambos Kalofonos; Athanasios Anagnostopoulos; Charalambos Deliveliotis; Dimitrios Bafaloukos; Meletios Athanasios Dimopoulos; Aristotelis Bamias
Journal:  Urology       Date:  2004-09       Impact factor: 2.649

10.  Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors.

Authors:  Dieter Kaag
Journal:  Lung Cancer       Date:  2012-11-04       Impact factor: 5.705
View more
  1 in total

1.  Clinically diagnosed primary transitional cell carcinoma of the colon: A case report.

Authors:  Ryuichi Taketomi; Naoto Ujiie; Yoshitaka Enomoto; Naruhito Takido; Yasushi Kawaharada; Masashi Zuguchi; Yosuke Kubota; Ken Saito
Journal:  Int J Surg Case Rep       Date:  2019-01-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.